Literature DB >> 20516361

Probable hypoglycemic adverse drug reaction associated with prickly pear cactus, glipizide, and metformin in a patient with type 2 diabetes mellitus.

Diana M Sobieraj1, Craig W Freyer.   

Abstract

OBJECTIVE: To report a case of an adverse drug reaction (ADR) in a patient with type 2 diabetes mellitus taking prickly pear cactus (PPC), glipizide, and metformin. CASE
SUMMARY: A 58-year-old Mexican male with type 2 diabetes mellitus being treated with metformin 1000 mg twice daily and extended-release glipizide 10 mg daily was referred to the pharmacist for medication education. He denied taking herbal supplements or experiencing hypoglycemia. Two hemoglobin A(1c) values (6.8% and 6.7%) obtained over the past year demonstrated glycemic control, which was supported by his reported fasting blood glucose readings of 113-132 mg/dL. One month later, the patient reported 4 hypoglycemic events with blood glucose readings of 49-68 mg/dL, which resulted in discontinuation of glipizide. One month later, the patient denied any further hypoglycemia. During medication reconciliation he reported consuming crude PPC pads daily for 2 months for glucose control. DISCUSSION: Literature suggests that PPC has an effect on lowering blood glucose levels in patients with type 2 diabetes mellitus, although few identified data describe ADRs from combining PPC with other agents used in treating type 2 diabetes mellitus. A literature search of MEDLINE (through December 2009) using the search terms diabetes mellitus, prickly pear cactus, nopal, opuntia, metformin, glipizide, glyburide, glimepiride, and sulfonylurea revealed no case reports of the described ADR. One case report describing the blood glucose-lowering effect of PPC in a patient concurrently taking oral antihyperglycemics documented an episode of hypoglycemia, although the Naranjo probability scale was not applied. One patient survey discovered the most common drug-herbal interaction in the given population to be between PPC and antihyperglycemic agents, resulting in hypoglycemia. In our case, use of the Naranjo probability scale suggests the ADR to be probable. The mechanism may be due to the additive glucose lowering of the 3 agents consumed concurrently by the patient.
CONCLUSIONS: Patients with type 2 diabetes mellitus should be routinely counseled about the use of herbal products to minimize the risk of ADRs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20516361     DOI: 10.1345/aph.1P148

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  5 in total

1.  Tes, Licuados, and Capsulas: herbal self-care remedies of Latino/Hispanic immigrants for type 2 diabetes.

Authors:  Karen A Amirehsani; Debra C Wallace
Journal:  Diabetes Educ       Date:  2013-09-12       Impact factor: 2.140

Review 2.  Critical evaluation of causality assessment of herb-drug interactions in patients.

Authors:  Charles Awortwe; Memela Makiwane; Helmuth Reuter; Christo Muller; Johan Louw; Bernd Rosenkranz
Journal:  Br J Clin Pharmacol       Date:  2018-01-29       Impact factor: 4.335

Review 3.  Interactions between antidiabetic drugs and herbs: an overview of mechanisms of action and clinical implications.

Authors:  Ramesh C Gupta; Dennis Chang; Srinivas Nammi; Alan Bensoussan; Kellie Bilinski; Basil D Roufogalis
Journal:  Diabetol Metab Syndr       Date:  2017-07-26       Impact factor: 3.320

Review 4.  Clinical Implications of Herbal Supplements in Conventional Medical Practice: A US Perspective.

Authors:  Gashaw Hassen; Gizeshwork Belete; Keila G Carrera; Rosemary O Iriowen; Haimanot Araya; Tadesse Alemu; Nebiyou Solomon; Diwas S Bam; Sophia M Nicola; Michael E Araya; Tadesse Debele; Michlene Zouetr; Nidhi Jain
Journal:  Cureus       Date:  2022-07-15

Review 5.  Clinical Potential of Fruit in Bladder Cancer Prevention and Treatment.

Authors:  Paulina Wigner; Michał Bijak; Joanna Saluk-Bijak
Journal:  Nutrients       Date:  2022-03-08       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.